$GEF

GEF Maintained by Wells Fargo -- Price Target Lowered to $88.00

Wells Fargo maintained an Equal-Weight rating on Greif (GEF) but lowered its price target to $88.00 from $90.00. GuruFocus values GEF at $54.17, suggesting a 49.1% overvaluation. The company has seen significant insider selling and has a GF Score of 64/100, indicating moderate performance with weak growth prospects.

Original reporting
Published Oct 19, 2026, 4:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 5:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$GEF
Bearish
medium confidence
Mentioned
$GEF
Relevance
6/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$GEFBearishLow
01

Why it matters

The rating maintenance with a lower target may trigger short‑term selling, but the Equal‑Weight stance suggests no immediate expectation of a major decline.

02

Market read

Analyst price‑target adjustments are modestly newsworthy; they can influence short‑term price action but are not a major catalyst.

03

What to watch

Potential upside from upcoming contract renewals or cost‑saving initiatives not captured in the rating update.

Relevance 6/10Novelty 5/10Timing: today

Background

Greif Inc. (GEF) is a $4.6 B industrial packaging company. The analyst note highlights overvaluation, modest growth, and recent insider selling.

Company-level read

Ticker impact

$GEFBearishMedium confidence
Context

Wells Fargo maintained an Equal-Weight rating on Greif Inc. and lowered its price target to $88.00, indicating a more cautious outlook.

Expected impact

likely pressure as investors price in the lower target

Evidence & confidence

Analyst price‑target cuts typically lead to short‑term sell‑offs, especially when combined with noted insider selling.

Market effects

Packaging and containers sector may see modest re‑rating pressure as peers adjust valuations.

U.S. industrial packaging stocks could experience slight downside sentiment.

Limited; impact confined to Greif and its immediate peers.

Counterpoint

Some investors may view the price‑target cut as an overreaction given Greif's strong cash flow generation.

Key entities

  • Wells Fargo

    Provided the rating update and new price target.

  • Greif Inc.

    Subject of the analyst rating change.

Related articles

$GEFHigh

Raymond James upgrades Greif stock on margin expansion outlook

Raymond James upgraded Greif (NYSE:GEF) to Outperform with a $90 price target, citing margin expansion potential and a strong balance sheet. The stock trades at $80.04, implying 12% upside. Greif's Q3 2026 revenue beat expectations at $1.17B, but EPS missed at $0.86. The company's dividend yield is 3.1%, with a 0.41 debt-to-equity ratio.

$GEFMed

Greif Reports Fiscal Third Quarter 2026 Results

GREIF, INC (GEF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Greif Reports Fiscal Third Quarter 2026 Results DELAWARE, Ohio (July 28, 2026) – Greif, Inc. (NYSE: GEF, GEF.B), a global leader in industrial packaging products and services, today announced fiscal third quarter 2026 results. On June 30, 2025, we entered into a defi

$GEFMed

Greif, Inc. Q3 2026 Earnings Call Summary

Strategic Execution and Operational Resilience Management attributed the 25% adjusted EBITDA growth and 260 basis point margin expansion to structural improvements rather than cyclical market recovery, which remains uneven. The company achieved its $90 million run rate cost optimization milestone ahead of schedule by simplifying the organization and optimizing the manufacturing network.

$MRNAHigh

MRNA Stock’s Vaccine Rally Cracks As Worst Week In 3 Months Looms — Analyst Calls It A ‘Do-Not-Trade’ Over Wild Swings

Moderna (MRNA) shares fell sharply, marking their worst week in three months. Analysts from Bernstein, TD Cowen, and BMO Capital Markets expressed mixed views on the company's cancer vaccine data, with price targets implying significant downside. Moderna reported a revenue decline in 2025 and aims for cash breakeven by 2028. Earnings are due on Nov. 6. Retail sentiment on Stocktwits remains bullish for both Moderna and Merck (MRK).

$RIOMed

Rio Tinto to invest USD1.9 billion in Kangwinan bauxite project

Rio Tinto PLC and Ltd will invest USD1.9 billion in the Kangwinan bauxite project in Queensland, Australia. The project aims to add 20 million tonnes of annual bauxite production capacity by 2032, replacing output from the Andoom mine. Construction is set to ramp up in 2027, supporting 1,300 jobs. Shares in Rio Tinto fell 2.2% to AUD147.05 in Sydney on Friday morning, according to the company and Alliance News.